Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis

Gastroenterology

Volumn 153, Issue 6, 2017, Pages 1568-1580.e10

  Kim, KyeongJin ^a   Ryu, Dongryeol ^b,c   Dongiovanni, Paola ^d   Ozcan, Lale ^a   Nayak, Shruti ^e   Ueberheide, Beatrix ^e,f   Valenti, Luca ^d   Auwerx, Johan ^b   Pajvani, Utpal B ^a  

^a Columbia University ^*  (United States)

^b EPFL   (Switzerland)

^c Pusan National University   (South Korea)

^d UNIVERSITY OF MILAN   (Italy)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Gene Regulation; Insulin Signaling; Signal Transduction; Triglyceride

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GLUCAGON; MESSENGER RNA; PHOSPHOPROTEIN PHOSPHATASE 2; PLECKSTRIN HOMOLOGY DOMAIN LEUCINE RICH REPEAT PROTEIN PHOSPHATASE 2; POTASSIUM CHANNEL; POTASSIUM CHANNEL TETRAMERIZATION DOMAIN CONTAINING 17; SERINE; SHORT HAIRPIN RNA; UNCLASSIFIED DRUG; KCTD17 PROTEIN, HUMAN; KCTD17 PROTEIN, MOUSE; PHLPP2 PROTEIN, HUMAN; PHLPP2 PROTEIN, MOUSE; PHOSPHOPROTEIN PHOSPHATASE; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

AKT SIGNALING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CRISPR-CAS9 SYSTEM; DOWN REGULATION; ENZYME DEGRADATION; ENZYME PHOSPHORYLATION; EXPERIMENTAL OBESITY; GENE DELETION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SILENCING; GENETIC TRANSDUCTION; GLUCONEOGENESIS; GLUCOSE TOLERANCE TEST; HEPATOMA CELL; HOMEOSTASIS MODEL ASSESSMENT; IMMUNOPRECIPITATION; INSULIN SIGNALING; LIPID DIET; LIPID LIVER LEVEL; LIPID STORAGE; LIPOGENESIS; LIQUID CHROMATOGRAPHY-MASS SPECTROMETRY; LIVER BIOPSY; LIVER CELL CULTURE; LIVER TISSUE; LOSS OF FUNCTION MUTATION; MALE; MOLECULAR PATHOLOGY; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PLECKSTRIN HOMOLOGY DOMAIN; PRIMARY CELL CULTURE; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SITE DIRECTED MUTAGENESIS; UPREGULATION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; COMPLICATION; DEFICIENCY; DIABETES MELLITUS; DISEASE MODEL; ENZYMOLOGY; GENETIC PREDISPOSITION; GENETICS; HEP-G2 CELL LINE; HUMAN; KNOCKOUT MOUSE; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; OBESITY; PATHOLOGY; PHENOTYPE; PHOSPHORYLATION; PROTEIN DEGRADATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DIABETES MELLITUS; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GLUCAGON; HEP G2 CELLS; HUMANS; LIPOGENESIS; LIVER; LIVER NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; PHENOTYPE; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; PROTEOLYSIS; SIGNAL TRANSDUCTION;

EID: 85035065060     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2017.08.039     Document Type: Article

References (49)

1. Pajvani, U.B., Accili, D., The new biology of diabetes. Diabetologia 58 (2015), 2459–2468.
2. Jelinek, L.J., Lok, S., Rosenberg, G.B., et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 259 (1993), 1614–1616.
3. Summers, S.A., Birnbaum, M.J., A role for the serine/threonine kinase, Akt, in insulin-stimulated glucose uptake. Biochem Soc Trans 25 (1997), 981–988.
4. Puigserver, P., Rhee, J., Donovan, J., et al. Insulin-regulated hepatic gluconeogenesis through FOXO1-PGC-1alpha interaction. Nature 423 (2003), 550–555.
5. Petersen, K.F., Laurent, D., Rothman, D.L., et al. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans. J Clin Invest 101 (1998), 1203–1209.
6. Saltiel, A.R., Kahn, C.R., Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001), 799–806.
7. Shimomura, I., Matsuda, M., Hammer, R.E., et al. Decreased IRS-2 and increased SREBP-1c lead to mixed insulin resistance and sensitivity in livers of lipodystrophic and ob/ob mice. Mol Cell 6 (2000), 77–86.
8. Matsumoto, M., Han, S., Kitamura, T., et al. Dual role of transcription factor FoxO1 in controlling hepatic insulin sensitivity and lipid metabolism. J Clin Invest 116 (2006), 2464–2472.
9. Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115 (2005), 1343–1351.
10. Li, S., Brown, M.S., Goldstein, J.L., Bifurcation of insulin signaling pathway in rat liver: mTORC1 required for stimulation of lipogenesis, but not inhibition of gluconeogenesis. Proc Natl Acad Sci U S A 107 (2010), 3441–3446.
11. Yecies, J.L., Zhang, H.H., Menon, S., et al. Akt stimulates hepatic SREBP1c and lipogenesis through parallel mTORC1-dependent and independent pathways. Cell Metab 14 (2011), 21–32.
12. Kim, K., Qiang, L., Hayden, M.S., et al. mTORC1-independent Raptor prevents hepatic steatosis by stabilizing PHLPP2. Nat Commun, 7, 2016, 10255.
13. Kersten, S., Mechanisms of nutritional and hormonal regulation of lipogenesis. EMBO Rep 2 (2001), 282–286.
14. Butler, P.C., Rizza, R.A., Contribution to postprandial hyperglycemia and effect on initial splanchnic glucose clearance of hepatic glucose cycling in glucose-intolerant or NIDDM patients. Diabetes 40 (1991), 73–81.
15. Dunning, B.E., Gerich, J.E., The role of alpha-cell dysregulation in fasting and postprandial hyperglycemia in type 2 diabetes and therapeutic implications. Endocr Rev 28 (2007), 253–283.
16. Ali, S., Drucker, D.J., Benefits and limitations of reducing glucagon action for the treatment of type 2 diabetes. Am J Physiol Endocrinol Metab 296 (2009), E415–E421.
17. Biddinger, S.B., Hernandez-Ono, A., Rask-Madsen, C., et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis. Cell Metab 7 (2008), 125–134.
18. Conarello, S.L., Jiang, G., Mu, J., et al. Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia. Diabetologia 50 (2007), 142–150.
19. Gao, T., Furnari, F., Newton, A.C., PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell 18 (2005), 13–24.
20. Grzechnik, A.T., Newton, A.C., PHLPPing through history: a decade in the life of PHLPP phosphatases. Biochem Soc Trans 44 (2016), 1675–1682.
21. Newton, A.C., Trotman, L.C., Turning off AKT: PHLPP as a drug target. Annu Rev Pharmacol Toxicol 54 (2014), 537–558.
22. Kasahara, K., Kawakami, Y., Kiyono, T., et al. Ubiquitin-proteasome system controls ciliogenesis at the initial step of axoneme extension. Nat Commun, 5, 2014, 5081.
23. Williams, E.G., Wu, Y., Jha, P., et al. Systems proteomics of liver mitochondria function. Science, 352, 2016, aad0189.
24. Ahrens, M., Ammerpohl, O., von Schonfels, W., et al. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery. Cell Metab 18 (2013), 296–302.
25. Pajvani, U.B., Qiang, L., Kangsamaksin, T., et al. Inhibition of Notch uncouples Akt activation from hepatic lipid accumulation by decreasing mTorc1 stability. Nat Med 19 (2013), 1054–1060.
26. Balasubramanian, D., Ohneck, E.A., Chapman, J., et al. Staphylococcus aureus coordinates leukocidin expression and pathogenesis by sensing metabolic fluxes via RpiRc. MBio, 2016, 7.
27. Bern, M., Kil, Y.J., Becker, C., Byonic: advanced peptide and protein identification software. Curr Protoc Bioinformatics, 2012 Chapter 13:Unit13.20.
28. Folch, J., Lees, M., Sloane Stanley, G.H., A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226 (1957), 497–509.
29. Mancina, R.M., Dongiovanni, P., Petta, S., et al. The MBOAT7-TMC4 variant rs641738 increases risk of nonalcoholic fatty liver disease in individuals of European descent. Gastroenterology 150 (2016), 1219–1230.e6.
30. Andreux, P.A., Williams, E.G., Koutnikova, H., et al. Systems genetics of metabolism: the use of the BXD murine reference panel for multiscalar integration of traits. Cell 150 (2012), 1287–1299.
31. Haeusler, R.A., Hartil, K., Vaitheesvaran, B., et al. Integrated control of hepatic lipogenesis versus glucose production requires FoxO transcription factors. Nat Commun, 5, 2014, 5190.
32. McKnight, G.S., Cyclic AMP second messenger systems. Curr Opin Cell Biol 3 (1991), 213–217.
33. Horton, J.D., Goldstein, J.L., Brown, M.S., SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002), 1125–1131.
34. Strable, M.S., Ntambi, J.M., Genetic control of de novo lipogenesis: role in diet-induced obesity. Crit Rev Biochem Mol Biol 45 (2010), 199–214.
35. Perry, R.J., Samuel, V.T., Petersen, K.F., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
36. Inaba, H., Goto, H., Kasahara, K., et al. Ndel1 suppresses ciliogenesis in proliferating cells by regulating the trichoplein-Aurora A pathway. J Cell Biol 212 (2016), 409–423.
37. Ji, A.X., Chu, A., Nielsen, T.K., et al. Structural insights into KCTD protein assembly and Cullin3 recognition. J Mol Biol 428 (2016), 92–107.
38. Valenti, L., Bugianesi, E., Pajvani, U., et al. Nonalcoholic fatty liver disease: cause or consequence of type 2 diabetes?. Liver Int 36 (2016), 1563–1579.
39. Leavens, K.F., Birnbaum, M.J., Insulin signaling to hepatic lipid metabolism in health and disease. Crit Rev Biochem Mol Biol 46 (2011), 200–215.
40. Lefebvre, P.J., Glucagon and its family revisited. Diabetes Care 18 (1995), 715–730.
41. Gelling, R.W., Du, X.Q., Dichmann, D.S., et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci U S A 100 (2003), 1438–1443.
42. Sloop, K.W., Cao, J.X., Siesky, A.M., et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 113 (2004), 1571–1581.
43. Sorensen, H., Brand, C.L., Neschen, S., et al. Immunoneutralization of endogenous glucagon reduces hepatic glucose output and improves long-term glycemic control in diabetic ob/ob mice. Diabetes 55 (2006), 2843–2848.
44. Tilg, H., Moschen, A.R., Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 52 (2010), 1836–1846.
45. Peverill, W., Powell, L.W., Skoien, R., Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 15 (2014), 8591–8638.
46. Buzzetti, E., Pinzani, M., Tsochatzis, E.A., The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism 65 (2016), 1038–1048.
47. Wang, X., Zheng, Z., Caviglia, J.M., et al. Hepatocyte TAZ/WWTR1 promotes inflammation and fibrosis in nonalcoholic steatohepatitis. Cell Metab 24 (2016), 848–862.
48. Kelly, R.P., Garhyan, P., Raddad, E., et al. Short-term administration of the glucagon receptor antagonist LY2409021 lowers blood glucose in healthy people and in those with type 2 diabetes. Diabetes Obes Metab 17 (2015), 414–422.
49. Kazierad, D.J., Bergman, A., Tan, B., et al. Effects of multiple ascending doses of the glucagon receptor antagonist PF-06291874 in patients with type 2 diabetes mellitus. Diabetes Obes Metab 18 (2016), 795–802.